Prodrug design to improve pharmacokinetic and drug delivery properties: Challenges to the discovery scientists

Current Medicinal Chemistry

Volumn 17, Issue 32, 2010, Pages 3874-3908

  Jana, S ^a   Mandlekar, S ^b   Marathe, P ^b  

^a SYNGENE INTERNATIONAL LTD   (India)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Absorption; Bioavailability; Carrier mediated transport; Drug targeting; Permeability; Prodrug; Solubility; Transporter

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMPICILLIN; AMPIROXICAM; AZATHIOPRINE; BACAMPICILLIN; BAMBUTEROL; BOPINDOLOL; CLADRIBINE; CLOFIBRATE; CYCLOPHOSPHAMIDE; DIPHENOXYLATE; DIPIVEFRINE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANINAMIVIR; LEVODOPA; LOSARTAN; MESTRANOL; OMEPRAZOLE; PIVAMPICILLIN; PRODRUG; PROGLUMETACIN; RABEPRAZOLE; SPIRAPRIL; SULINDAC; TARIBAVIRIN; TENOFOVIR DISOPROXIL; TERBUTALINE; TERFENADINE; UNINDEXED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; ASTHMA; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LIPOPHILICITY; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; PHARMACOKINETICS; STOMACH SECRETION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DESIGN; MEMBRANE TRANSPORT PROTEINS; PRODRUGS;

EID: 78650655889     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793205426     Document Type: Article

References (148)

1. Notari, R. E. Prodrug design. Pharmacol. Ther., 1981, 14, 25-53.
2. Lee, H. J.; You, Z.; Ko, D. H.; McLean, H. M. Recent advances in prodrugs and antedrugs. Curr. Opin. Drug Discov. Dev., 1998, 1, 235-244.
3. Anderson, B. D.; Conradi, R. A.; Knuth, K. E.; Nail, S. L. Strategies in the design of solution-stable, water-soluble prodrugs. II: properties of micellar prodrugs of methylprednisolone. J. Pharm. Sci., 1985, 74, 375-381.
4. Hsieh, P. W.; Hung, C. F.; Fang, J. Y. Current prodrug design for drug discovery. Curr. Pharm. Des., 2009, 15, 2236-2250.
5. Testa, B. Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Curr. Opin. Chem. Biol, 2009, 13, 1-7.
6. Testa, B.; Mayer, J. M. Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology. Weinheim, Federal Republic of Germany: Wiley-VCH, 2003.
7. Wu, K.-M. A New Classification of Prodrugs: Regulatory Perspectives. Pharmaceuticals, 2009, 2, 77-81.
8. Wu, K. M.; Farrelly, J. Regulatory perspectives of type II prodrug development and time-dependent toxicity management: Nonclinical pharm/tox analysis and the role of comparative toxicology. Toxicology, 2007, 236, 1-6.
9. Wermuth, C. G. Designing prodrugs and bioprecursors. Drug Design: Fact or Fantasy. Academic Press, London, 1984, pp. 47-72.
10. Duggan, D. E.; Hooke, K. F.; Hwang, S. S. Kinetics of the tissue distributions of sulindac and metaboites. Drug Metab. Dispos., 1980, 8, 241-246.
11. Wong, P. C.; Price, W. A. Jr.; Chiu, A. T.; Duncia, J. V.; Corini, D. J.; Wexler, R. R.; Johnson, A. L.; Timmermans, PB. Nonpeptide angiotension II receptor antagonists. XI. Pharmacology of Exp 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 1990, 255, 211-217.
12. Bohnenstengel, F.; Hofmann, U.; Eichelbaum, M.; Kroemer, H. K. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur. J. Clin. Pharmacol, 1996, 51, 297-301.
13. Samuelson, J. Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother., 1999, 43, 1533-1541.
14. Thompson, A. M.; Blaser, A.; Anderson, R. F.; Shinde, S. S.; Franzblau, S. G.; Ma, Z.; Denny, W. A.; Palmer, B. D. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6, 7-dihydro-5H-imidazo[2, 1-b][1, 3]oxazine (PA-824). J. Med. Chem., 2009, 52, 637-645.
15. Hall, M. D.; Mellor, H. R.; Callaghan, R.; Hambley, T. W. Basis for design and development of platinum (IV) anticancer complexes. J. Med. Chem., 2007, 50, 3403-3411.
16. Anderson, R. F.; Shinde, S. S.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Activation of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc, 2003, 125, 748-756.
17. Testa, B. Prodrug research: futile or fertile? Biochem. Pharmacol, 2004, 68, 2097-2106.
18. Testa, B. Prodrugs. In drug bioavailability-estimation of solubility, permeability, absorption and bioavailability, Edn 2. Wiley-VCH, 2008, 559-570.
19. Stella, V. J.; Borchardt, R. T.; Hagemen, M.; Oliyai, R.; Maag, H.; Tilley, J. Prodrugs: Challenges and rewards, in the "Biotechnology: Pharmaceutical Aspects" series. New York, NY: Springer/AAPS Press, 2007, Vol. 5.
20. Lavis, L. D. Ester bonds in prodrugs. ACS Chem. Biol, 2008, 3, 1-3.
21. Silva, A. T.dA.; Chung, M. C.; Castro, L. F.; Güido, R. V. C.; Ferreira, L. I. Advances in prodrug design. Mini-Rev. Med. Chem., 2005, 5, 893-914.
22. Krise, J. P.; Zygmunt, J.; Georg, G. I.; Stella, V. J. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl Prodrugs. J. Med. Chem., 1999, 42, 3094-3100.
23. Fleisher, D.; Bong, R.; Stewart, B. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev., 1996, 19, 115-130.
24. Clayton, J. P., Cole, M., Elson, S. W.; Ferres, H.; Hanson, J. C.; Mizen, L. W.; Sutherland, R. Preparation, hydrolysis, and oral absorption of lactonyl esters of penicillins. J. Med. Chem., 1976, 19, 1385-1391.
25. Ferres H. Prodrugs of β-Lactam Antibiotics. Drugs Today, 1983, 19, 499-538.
26. Ehrnebo, M.; Nilsson, S. O.; Boreus, L. O. Pharmacokinetics of ampicillin and its Prodrugs bacampicillin and pivampicillin in man. J. Pharmacokinet. Biopharm., 1979, 7, 429-451.
27. Beaumont, K.; Webster, R.; Gardner, I,.; Dack, K. Design of ester Prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab., 2003, 4, 461-485.
28. Svensson, L.; Tunek, A. The design and bioactivation of presystemically stable prodrugs. Drug Metab. Rev., 1988, 19, 165-194.
29. Tunek, A.; Levin, E.; Svensson, L. Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem. Pharmacol., 1988, 37, 3867-3876.
30. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov., 2008, 7, 255-270.
31. van De Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem., 2001, 44, 1313-1333.
32. Schultz, C. Prodrugs of biologically active phosphate esters. Bioorg. Med. Chem., 2003, 11, 885-898.
33. Guarino, V. R. Sulfenamide Prodrugs: A novel prodrug approach for amides, imides and other NH-acidic compounds, The University of Kansas, Lawrence (KS), 2004.
34. Ettmayer, P.; Amidon, G.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem., 2004, 47, 2393-2404.
35. Liederer, B. M.; Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci., 2006, 95, 1177-1195.
36. Berry, L. M.; Wollenberg, L.; Zhao, Z. Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab. Lett., 2009, 3, 70-77.
37. Taylor, M. D. Improved passive oral drug delivery via prodrugs. A case for prodrugs: fosphenytoin. Adv. Drug Deliv. Rev., 1996, 19, 131-148.
38. Sinkula, A. A.; Yalkowsky, S. H. Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci., 1975, 64, 181-210.
39. Donn, K. H.; James, N. C.; Powell, J. R. Bioavailability of cefuroxime axetil formulations. J. Pharm. Sci., 1994, 83, 842-844.
40. ®): Profile of a Corticosteroid. J. Cutaneous Med. Surg., 2004, 8, 244-249.
41. Meredith, P. A. Candesartan cilexetil - a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr. Med. Res. Opin., 2007, 23, 1693-1705.
42. Potter, P. M.; Wadkins, R. M. Carboxylesterases detoxifying enzymes and targets for drug therapy. Curr. Med. Chem., 2006, 13, 1045-1054.
43. Heimbach, T.; Oh, D.-M.; Li, L. Y.; Rodriguez-Hornedo, N.; Garcia, G.; Fleisher, D. Enzyme-Mediated Precipitation of Parent Drugs from Their Phosphate Prodrugs. Int. J. Pharm., 2003, 261, 81-92.
44. Anastasi, C.; Quéléver, G.; Burlet, S.; Garino, C.; Souard, F.; Kraus, J. L. New antiviral nucleoside prodrugs await application. Curr. Med. Chem., 2003, 10, 1825-1843.
45. Périgaud C.; Gosselin G.; Imbach, J.-L. Minireview: from the pronucleotide concept to the SATE. Curr. Top. Med. Chem., 1997, 2, 15-29.
46. Kukhanova, M.; Krayevsky, A.; Prusoff, W.; Cheng, Y.-C. Design of Anti-HIV Compounds from Nucleoside to Nucleoside 5-Triphosphate Analogs. Problems and Perspectives. Curr. Pharm. Des., 2000, 6, 585-598.
47. Shaffiee, M.; Deferme, S.; Villard, A.-L.; Egron, D.; Gosselin, G.; Imbach, J.-L.; Lioux, T.; Pompon, A.; Varray, S.; Aubertin, A.-M.; Van den Mooter, G.; Kinget, R.; Périgaud, C.; Augustijns, P. New bis (SATE) prodrug of AZT 5'-monophosphate: In vitro anti-HIV activity, stability, and potential oral absorption. J. Pharm. Sci., 2000, 90, 448-463.
48. Dore, G. J.; Cooper, D. A.; Pozniak, A. L.; DeJeus, E.; Zhong, L.; Miller, M. D.; Lu, B.; Cheng, A. K. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy naïve and experienced patients coinfected with HIV-I and hepatitis B virus. J. Infect. Diseases, 2004, 189, 1185-1192.
49. Benhamou, Y.; Thibault, V.; Vig, P.; Calvez, V.; Marcelin, A.; Fievet, M.; Currie, G.; Chang, C.; Biao, L.; Xiong, S. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudineresistant hepatitis B and HIV-1. J. Heptatol., 2006, 44, 62-67.
50. Benhamou, Y.; Bochet, M.; Thibault, V.; Calvez, V.; Fievet, M. H.; Vig, P.; Gibbs, C. S.; Brosgart, C.; Fry, J.; Namini, H.; Katiama, C.; Poynard, T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet, 2001, 358, 718-723.
51. Vlieghe, P.; Bihel, F.; Clerc, T.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.; Salles, J.-P.; Chermann, J.-C.; Kraus, J.-L. New 3'-Azido-3'-deoxythymidin-5'-yl O-(coHydroxyalkyl) Carbonate Prodrugs: Synthesis and Anti-HIV Evaluation. J. Med. Chem., 2001, 44, 777-786.
52. Vlieghe, P.; Clerc, T.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.; Salles, J.-P.; Chermann, J.-C.; Kraus, J.-L. New 3'-Azido-3'-deoxythymidin-5'-yl O-(ω-Hydroxyalkyl or-Alkenyl or Alkylepoxide) Carbonate Prodrugs: Synthesis and Anti-HIV Evaluation. J. Med. Chem., 2001, 44, 3014-3021.
53. Chamorro, C.; Pérez-Pérez, M.-J.; Rodriguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.-J. Exploring the role of the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives. Antiviral Res., 2001, 50, 207-222.
54. Ecobichon, D. Relative amounts of hepatic and renal carboxylesterase in mammalian species. Res. Commun. Chem. Pathol. Pharmacol, 1972, 3, 629-636.
55. Weitz, J. I.; Crowther, M. Direct thrombin inhibitors. Thromb. Res., 2002, 106, V275-V284.
56. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J. M.; Wienen, W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem., 2002, 45, 1757-1766.
57. Mungall, D. BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs, 2002, 3, 905-907.
58. Steffansen, B.; Nielsen, C. U.; Brodin, B.; Eriksson, A. H.; Andersen, R.; Frokjaer, S. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci., 2004, 21, 3-16.
59. Tano, K.; Yoshizumi, M.; Kitagawa, T.; Hori, T.; Kitaichi, T.; Itoh, K.; Katoh, I. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery. Life Sci., 1997, 61, 1469-1478.
60. Nishiyama, S.; Yamaguchi, I.; Akimoto, Y.; Yoshikawa, M.; Nakajima, H. A novel orally active dopamine prodrug TA-870 II. Evidence that TA-870 is a dopamine prodrug. J. Cardiovasc. Pharmacol, 1989, 14, 175-183.
61. Matsubayashi, K.; Ueda, Y.; Ogino, H.; Sugita, T.; Sakakibara, Y.; Matsuyama, K.; Nomoto, T. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac. Cardiovasc. Surg., 1999, 47, 352-356.
62. Nishiyama, S.; Yoshikawa, M.; Yamaguchi, I. An orally effective peripheral dopamine prodrug-Docarpamine TA-870. Cardiovasc. Drug Rev., 1992, 10, 101-116.
63. Järvinen, T.; Järvinen, K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 1996, 19, 203-224.
64. Gogate, U. S.; Repta, A. J.; Alexander, J. N-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs for amines. I. Kinetics and mechanism of degradation in aqueous solutions. Int. J. Pharm., 1987, 40, 235-248.
65. Krise, J. P.; Zygmunt, J.; Georg, G. I.; Stella, V. J. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. J. Med. Chem. 1999, 42, 3094-3100.
66. Krise, J. P.; Charman, W. N.; Charman, S. A.; Stella, V. J. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. J. Pharm. Sci., 1999, 88, 928-932.
67. Simplício, A. L.; John M, Clancy, L. M.; Gilmer, J. F. β-Aminoketones as prodrugs with pH-controlled activation. Int. J. Pharm., 2007, 336, 208-214.
68. Bundgaard, H.; Johansen, M. Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents. Int. J. Pharm., 1981, 9, 7-16.
69. Bundgaard, H.; Johansen, M. Prodrugs as drug delivery systems IV: N-mannich bases as potential novel prodrugs for amides, ureides, amines, and other NH-acidic compounds. J. Pharm. Sci., 1980, 69, 44-46.
70. Clement, B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab. Rev., 2002, 34, 565-579.
71. Thorneycroft, I. H. Noncontraceptive benefits of modern low-dose oral contraceptives. Adv. Contracept., 1992, 8, 5-12.
72. Carlsson, S. C.; Mattsson, C.; Eriksson, U. G.; Sarich, T. C.; Wahlander, K.; Eliasson, A.; Karlson, B. W.; Sheth, S. B.; Held, P. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb. Res., 2005, 115, 9-18.
73. Gustafsson, D.; Elg, M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res., 2003, 109, S8-S15.
74. Eriksson, U. G.; Bredberg, U.; Hoffman, K. J.; Thuresson, A.; Gabrielsson, M.; Ericsson, H.; Ahnoff, M.; Gilsen, K.; Fager, G.; Gustafsson, D. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos., 2003, 31, 294-305.
75. Lipinski, C. Poor solubility - an industry wide problem in drug discovery. Am. Pharm. Rev., 2002, 5, 82-85.
76. Lennernas, H. Intestinal drug absorption and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol., 2003, 55, 429-433.
77. Peterson, L. W.; McKenna, C. E. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin. Drug Deliv., 2009, 6, 405-419.
78. Amidon, G. L.; Leesman, G. D.; Elliott, R. L. Improving intestinal absorption of water-insoluble compounds: A membrane metabolism strategy. J. Pharm. Sci., 1980, 69, 1363-1368.
79. Ajaj, K. A.; Kratz, F. Development of dual-acting prodrugs for circumventing multidrug resistance. Bioorg. Med. Chem. Lett., 2009, 19, 995-1000.
80. Vinsova, J.; Vavrikova, E. Recent advances in drugs and prodrugs design of chitosan. Curr. Pharm. Des., 2008, 14, 1311-1326.
81. Halen, P. K.; Murukumar, P. R.; Giridhar, R.; Yadav, M. R. Prodrug designing of NSAIDS. Mini Rev. Med. Chem., 2009, 1, 124-139.
82. Vierling, P.; Greiner, J. Prodrugs of HIV protease inhibitors. Curr. Pharm. Des., 2003, 9, 1755-1770.
83. Kearney, B. P.; Flaherty, J. F.; Shah, J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet., 2004, 43, 595-612.
84. Mackman, R. L.; Cihlar, T. Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annu. Rep. Med. Chem., 2004, 39, 305-321.
85. Yuan, H.; Li, N.; Lai, Y. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. Drug Metab. Dispos., 2009, 37, 1443-1447.
86. Stella, V. J. A case for prodrugs: fosphenytoin. Adv. Drug Deliv. Rev., 1996, 19, 311-330.
87. Brouwers, J.; Tack, J.; Augustijns, P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the caco-2 system: Illustration of intraluminal supersaturation. Int. J. Pharm., 2007, 366, 302-309.
88. Wire, M. B.; Shelton, M. J.; Studenberg, S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet., 2006, 45, 137-168.
89. Fleisher, D.; Stewart, B. H.; Amidon, G. L. Design of Prodrugs for Improved Gastrointestinal Absorption by Intestinal Enzyme Targeting. Methods Enzymol., 1985, 112, 360-381.
90. Wang, W.; Jiang, J.; Ballard, C. E.; Wang, B. Prodrug approaches in the improved delivery of peptide drugs. Curr. Pharm. Des., 1999, 5, 265-287.
91. Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kimura, T.; Kiso, Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: Design and synthesis of isotaxel. J. Med. Chem., 2004, 47, 3782-3784.
92. Skwarczynski, M.; Sohma, Y.; Noguchi, M.; Kimura, M.; Hayashi, Y.; Hamada, Y.; Kimura, T.; Kiso, Y. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions. J. Med. Chem., 2005, 48, 2655-2666.
93. Yang, C.; Tirucherai, G. S.; Mitra, A. K. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther., 2001, 1, 159-175.
94. Anand, B. S.; Dey, S.; Mitra, A. K. Current prodrug strategies via membrane transporters/receptors. Expert Opin. Biol. Ther., 2002, 2, 607-620.
95. Smith, D. A. Do prodrugs deliver? Curr. Opin. Drug Discov. Dev., 2007, 10, 550-559.
96. Mizuma, T.; Ohta, K.; Hayashi, M.; Awazu, S. Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs. Biochem. Pharmacol, 1992, 43, 2037-2039.
97. Tsuji, A.; Tamai, I.; Nakanishi, M.; Amidon, G. L. Mechanism of absorption of the dipeptide-methyldopa-phe in the intestinal brushborder membrane vesicles. Pharm. Res., 1990, 7, 1313-1319.
98. Inui, K.; Terada, T.; Masuda, S.; Saito, H. Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant., 2000, 15, 11-13.
99. Santos, C. R.; Capela, R.; Pereira, C. S. G. P.; Valente, E.; Gouveia, L.; Pannecouque, C.; De Clercq, E.; Moreira, R.; Gomes, P. Structure-activity relationships for dipeptide prodrugs of acyclovir: Implications for prodrug design. Eur. J. Med. Chem., 2009, 44, 2339-2346.
100. Swaan, P. W.; Tukker, J. J. Carrier-mediated transport mechanism of foscarnet in rat intestinal tissue. J. Pharmacol. Exp. Ther., 1995, 272, 242-247.
101. Yang, C. Y.; Dantzig, A. H.; Pidgeon, C. Intestinal peptide transport systems and oral drug bioavailability. Pharm. Res., 1999, 16, 1331-1343.
102. Lee, V. H. Membrane-transporters. Eur. J. Pharm. Sci., 2000, 11, S41-S50.
103. Swaan, P. W.; Tukker, J. J. Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci., 1997, 86, 596-602.
104. Ganapathy, M. E.; Brandsch, M.; Prasad, P. D.; Ganapathy, V.; Leibach, F. H. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT2. J. Biol. Chem., 1995, 270, 25672-25677.
105. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci., 2008, 97, 1109-1134.
106. Tsuda, M.; Terada, T.; Irie, M.; Katsura, T.; Niida, A.; Ttomita, K.; Fujii, N.; Inui, K.-I. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J. Pharmacol. Exp. Ther., 2006, 318, 455-460.
107. Cundy, K. C.; Annamalai, T.; Bu, L.; de Vera, J.; Estrela, J.; Luo, W.; Shirsat, P.; Torneros, A.; Yao, F.; Zou, J.; Barrett, R. W.; Gallop, M. A. XP13512, a novel gabapentin prodrug: II. improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther., 2004, 311, 324-333.
108. Cundy, K. C.; Sastry, S.; Luo, W.; Zou, J.; Moors, T. L.; canafax, D. M. Clinical pharmacokinetics of XP13512, a Novel transported Prodrug of Gabapentin. J. Clin. Pharmacol, 2008, 48, 1378-1388.
109. Merlino, G.; Serafini, A.; Young, J. J.; Robiony, F.; Gigli, L. G.; Valente, M. Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symtoms associated with disorders such as restless leg syndrome. Curr. Opin. Invest. Drug, 2009, 10, 91-102.
110. Stella, V. J. Prodrugs as therapeutics. Expert Opin. Ther. Pat., 2004, 14, 277-280.
111. Shinhababu, A.; Thakker, D. Prodrug of anticancer agents. Adv. Drug Deliv. Rev., 1996, 19, 241-273.
112. Magnan, S. D. J., Shirota, F. N.; Nagasawa, H. T. Drug latentiation by y-glutamyl transpeptidase. J. Med. Chem., 1982, 25, 1018-1021.
113. Bodor, N.; Abdelalim, A. M. Improved delivery through biological membrane XIX: novel redox carriers for brain specific chemical delivery systems. J. Pharm. Sci., 1985, 74, 241-245.
114. Chu, C. K.; Bhadti, V. S.; Doshi, K. J.; Etse, J. T.; Gallo, J. M.; Boudinot, F. D.; Schinazi, R. F. Brain targeting of ant-HIV nucleosides. J. Med. Chem., 1990, 33, 2188-2192.
115. Singh, G.; Sharma, PD. Mutual prodrugs: a recent trend in prodrug design. Indian J. Pharm. Sci., 1994, 56, 69-79.
116. Chung, M. C.; Güido, R. V.; Martinelli, T. F.; Goncalves, M. F.; Polli, M. C.; Botelho, K. C. A.; Varanda, E. A.; Colli, W.; Miranda, M. T.; Ferreira, E. I. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem., 2003, 3, 4779-4783.
117. Sing, Y.; Palombo, M.; Sinko, P. J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem., 2008, 15, 1802-1826.
118. Han, H. K.; Amidon, G. L. Targeted prodrug design to optimize drug delivery. AAPS Pharm. Sci., 2000, 2, 1-11.
119. Ito, T.; Tanabe, K.; Yamada, H.; Hatta, H.; Nishimoto, S.-C. Radiation-and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors. Molecules, 2008, 13, 2370-2384.
120. Denny, W. A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest., 2004, 22, 604-619.
121. Napier, M. P.; Sharma, S. K.; Springer, C. J.; Bagshawe, K. D.; Green, A. J.; Martin, J.; Stribbling, S. M.; Cushen, N.; O'Malley, D.; Begent, R. H. Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res., 2000, 6, 765-772.
122. Rooseboom, M.; Commandeur, J. N.; Vermeulen, N. P. Enzymecatalyzed activation of anticancer prodrugs. Pharmacol. Rev., 2004, 56, 53-102.
123. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res., 2001, 7, 3314-3324.
124. Encell, L. P.; Landis, D. M.; Loeb, L. A. Improving enzymes for gene therapy. Nat. Biotechnol, 1999, 17, 143-147.
125. Erion, M. D.; Bullough, D. A.; Lin, C. C.; Hong, Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr. Opin. Investig. Drugs, 2006, 7, 109-117.
126. Huttunen, K. M.; Mahonen, N.; Raunio, H.; Rautio, J. Cytochrome P450-activated prodrugs: targeted drug delivery. Curr. Med. Chem., 2008, 15, 2346-2365.
127. Shitara, Y.; Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther, 2006, 112, 71-105.
128. Stella, V. J. Prodrugs: some thoughts and current issues. J. Pharm. Sci., 2010, 99, 1-11.
129. http://www.medicalnewstoday.com/articles
130. http://clinicaltrials.gov
131. Pao, L. H.; Hsiong, C. H.; Hu, O. Y.; Wang, J. J.; Ho, S. T. In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. Drug Metab. Dispos., 2005, 33, 395-402.
132. Meunier, B., de Visser, S. P.; Shaik, S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev., 2004, 104, 3947-3980.
133. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev., 2007, 59, 677-694.
134. Leppanen, J.; Huuskonen, J.; Savolainen, J.; Nevalainen, T.; Taipale, H.; Vepsalainen, J.; Gynther, J.; Jarvinen, T. Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett., 2000, 10, 1967.
135. Feng, X.; Yuan, Y.; Wu, J. Synthesis and Evaluation of Water-Soluble Paclitaxel Prodrugs. Bioorg. Med. Chem. Lett., 2002, 12, 3301-3303.
136. Hu, L. The prodrug approach to better targeting. In Meeting Report of Prodrugs: Effective solutions for solubility, permeability, and targeting challenges, 28-29 June 2004, Philadelphia, PA, USA.; www.currentdrugdiscovery. com, accessed on 8 August 2009.
137. Xu, G.; Zhang, W.; Ma, M. K.; McLeod, H. L. Human carboxylase 2 is commonly expressed in tumor tissue and is correlated with activation of irrinotecan. Clin. Cancer Res., 2002, 8, 2605-2611.
138. Michael, M.; Doherty, M. M. Ttumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol., 2005, 23, 205-229.
139. Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol., 2001, 14, 611-650.
140. Gorrod, J. W. Potential hazards of the prodrug approach. Chem. Ind., 1980, 457-461.
141. Dhareshwar, S. S.; Stella, V. J. Your prodrug releases formaldehyde: should you be concerned? No. J. Pharm. Res., 2008, 97, 4184-4193.
142. Brass, E. P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev., 2002, 54, 589-598.
143. Safadi, M.; Oliyai, R.; Stella, V. Phosphoryloxymethyl carbamates and carbonates-novel water-soluble prodrugs for amines and hindered alcohols. Pharm. Res., 1993, 10, 1350-1355.
144. Badawy, S. I.; Williams, R. C.; Gilbert, D. L. Chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. J. Pharm. Sci., 1999, 88, 428-433.
145. Yuan, L.-C.; Dahl, T. C.; Oliyai, R. Effect of carbonate salts on the kinetics of acid-catalyzed dimerization of adefovir dipivoxil. Pharm. Res., 2000, 17, 1098-1103.
146. Gallant, J. E.; Deresinski, S. Tenofovir disoproxil fumarate. Clin. Infect. Dis., 2003, 37, 944-950.
147. Gu, L.; Strickley, R. G. Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. Pharm. Res., 1987, 4, 392-397.
148. Varia, S. A.; Schuller, S.; Sloan, K. B.; Stella, V. J. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci., 1984, 73, 1068-1073.